Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique ACC platform technology to address gaps in cancer care, enabling medical communities to effectively combat and improve cancer treatment outcomes. View on: LinkedIn.com | Sales Navigator.

New Funding Raised: $100M, Series D

Round Investors: Digital Mobile Venture (lead)

🚀Growth Focus: Support expansion and progress of the oncology pipeline, including ACE1831 and ACE2016, antibody-armed allogeneic gamma delta T-cell therapies.

Press: PR Newswire, Fierce Biotech

HQ: Alameda, CA

Industry: Biotechnology Research

Employee Count: 39